prostaglandin-d2 and fexofenadine

Nasal obstruction is one of the most bothersome symptoms of allergic rhinitis (AR) affecting sleep-related quality of life in AR patients. Although several treatments were tested to control nasal obstruction, some patients with moderate to severe AR do not respond to current treatments, including the combined administration of different types of anti-allergic medicine. Thus, new options for AR treatment are needed. This study aimed to evaluate the effects of combined treatment with a novel inhibitor of hematopoietic prostaglandin D synthase (HPGDS), TAS-205, and different types of anti-allergic medicine on nasal obstruction in AR. Firstly, we demonstrated that TAS-205 selectively inhibited prostaglandin D

Topics: Acetates; Animals; Anti-Allergic Agents; Cell Line; Cyclopropanes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Guinea Pigs; Humans; Intramolecular Oxidoreductases; Lipocalins; Male; Morpholines; Nasal Mucosa; Nasal Obstruction; Ovalbumin; Piperidines; Prostaglandin D2; Pyrroles; Quality of Life; Quinolines; Rats; Rhinitis, Allergic; Sulfides; Terfenadine

Topics: Anti-Inflammatory Agents; Butyrophenones; Cells, Cultured; Cetirizine; Chymases; Eosinophils; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Histamine; Histamine H1 Antagonists; Humans; Hypersensitivity; Intercellular Adhesion Molecule-1; Interleukin-3; Interleukin-8; Loratadine; Mast Cells; Piperidines; Potassium Channel Blockers; Potassium Channels; Prostaglandin D2; Pyridines; Recombinant Fusion Proteins; Recombinant Proteins; Serine Endopeptidases; Terfenadine; Time Factors; Tryptases